ICU Medical (NASDAQ:ICUI) Director Elisha Finney Sells 1,285 Shares

ICU Medical, Inc. (NASDAQ:ICUI) Director Elisha Finney sold 1,285 shares of the company’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the transaction, the director owned 3,995 shares of the company’s stock, valued at $560,977.90. The trade was a 24.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

ICU Medical Stock Down 2.8%

ICUI opened at $139.15 on Thursday. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $196.26. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63. The business’s 50-day moving average price is $124.98 and its 200-day moving average price is $128.32. The company has a market cap of $3.44 billion, a P/E ratio of -91.55 and a beta of 0.83.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The business had revenue of $533.30 million during the quarter, compared to analyst estimates of $511.46 million. During the same quarter in the prior year, the company posted $1.59 EPS. ICU Medical’s quarterly revenue was down 8.9% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. On average, equities analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current year.

Institutional Trading of ICU Medical

Several hedge funds have recently bought and sold shares of the stock. Cullen Frost Bankers Inc. purchased a new position in shares of ICU Medical in the second quarter valued at about $38,000. SJS Investment Consulting Inc. boosted its stake in ICU Medical by 41,000.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock worth $49,000 after purchasing an additional 410 shares during the period. Covestor Ltd raised its position in shares of ICU Medical by 70.7% during the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock valued at $68,000 after buying an additional 236 shares during the last quarter. Blue Trust Inc. raised its position in shares of ICU Medical by 17.6% during the second quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock valued at $124,000 after buying an additional 141 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after buying an additional 101 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Piper Sandler lifted their target price on shares of ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a research report on Wednesday, October 8th. Raymond James Financial cut their target price on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. KeyCorp boosted their price target on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a report on Friday, September 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, ICU Medical currently has a consensus rating of “Moderate Buy” and an average price target of $181.75.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.